Dr. Mikhail Blagosklonny is a physician-scientist. He performs his research and is a professor of Oncology at the Roswell Park Cancer Institute. Dr. Blagoskionny is an expert in the areas of aging and cancer and has over 300 published articles including reviews and books.
He was awarded both an M.D. in Internal Medicine and Ph.D.. from the First Pavlov State Medical University of St. Petersburg, in Russia. His Ph.D. studies were in Experimental Medicine and Cardiology. In 2002, he was employed at New York Medical College as an associate professor of medicine. The Ordway Research Institute offered Dr. Blagosklonny, a position as a senior research scientist and serves as the Professor of Oncology in 2009.
Dr. Blagosklonny’s research interests included studying the mechanisms of aging and anti-aging drugs. As an oncologist and scientist, he is studying specific targeted cancer therapies to protect healthy cells from being damaged. His research interests also include cell cyclotherapy and chemotherapeutic engineering. Cyclotherapy is a technique to improve cancer treatments by tracking the dose-limiting side effects of chemotherapy. His ultimate research goal is to discover the underlying mechanisms of curing cancer. Read more on templeofthecave.com
Dr. Blagosklonny’s passion is to control aging and is seriously studying a drug that suppresses cell function, which has anti-aging implications. Scientist muse that he is looking for the drug that acts like the “fountain of youth.”
The research questions being asked are sublime such as, what is the cause of human death? There is a debate as to what is the ultimate cause of death. Should death be treated as if it were a disease? These are the questions that Dr. Blagosklonny is seeking answers.
The prevailing view is that aging is a decline in function as a result of random molecular damage and this decline cannot be prevented. An aging cell is one that has lost its power to divide and grow. Random molecular damage is the key because an anti-aging drug presumes that molecular damage, as one age, is not random.
Dr. Mikhail Blagosklonny is challenging that presumption with his ant-aging research that explores the effectiveness of the drug, rapamycin. He has proposed a hyperfunction theory and postulated that aging is a continuation of growth. The drug rapamycin or its analogue is then used to treat aging by preventing diseases. Thus, if this proves true, all that one would have to do is to decide the proper dosage of rapamycin to extend the human lifespan. Check Mikhail’s profile in LinkedIn
The research community is not convinced that Dr. Blagosklonny was on the right track. However, he continued with his research on anti-aging with rapamycin. It is important to note that rapamycin has been approved for clinical usage to treat organ transplant rejection. Has Dr. Mikhail Blagosklonny found the fountain of youth?